Raptim Research

What Raptim Research does

Raptim Research Private Limited is a privately held, India-based full-service contract research organization (CRO) founded in 2005 in Navi Mumbai by Dr. Rajen Shah and Mr. Viraj Shah. The company delivers end-to-end clinical development services spanning Phase I-IV clinical trials, bioavailability/bioequivalence (BA/BE) studies, in-vitro studies (IVRT/IVPT), and specialty studies (glucose clamp, dermal microdialysis, skin blanching), supported by a bioanalytical laboratory with 600+ validated methods. Its infrastructure includes 390 clinical beds across 50,000 sq.ft. in Mumbai and Gandhinagar, plus a US business development office in Skillman, New Jersey.

The company serves pharmaceutical, biotechnology, medical device, and consumer healthcare sponsors globally, with horizontal segmentation across 18+ therapeutic areas. Its technology stack combines clinical facilities, bioanalytical laboratories (LC-MS/MS, Franz diffusion cells with 14 consoles and 288 cells), and compliant data systems (SDMS/LIMS, eLab notebooks, CFR 21 Part 11-validated software). Raptim's regulatory track record includes 32+ USFDA inspections cleared, 64 total regulatory inspections across USFDA, MHRA, WHO, ANVISA, NPRA, BfArM, HPRA, CHILE, DCGI, NABL, and GCC, and 5 USFDA-approved IVPT studies.

The business operates on project-based, quote-priced professional services engagements, with multi-year contracts typical for clinical trial sponsors. GTM is sales-led via direct enterprise business development (India and US offices), industry events, and sponsor referrals driven by its regulatory reputation. Revenue is not publicly disclosed; the company is founder-owned without external institutional capital.

Name

Raptim Research

Legal name

Raptim Research Private Limited

Website

https://raptimresearch.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Raptim Research is a privately held, India-based full-service CRO founded in 2005, providing Phase I-IV clinical trials, BA/BE studies, in-vitro studies, and bioanalytical services to pharmaceutical, biotech, and medical device sponsors globally, with 32+ USFDA inspections cleared.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)

Keywords

• Contract research organization
• Clinical trial services
• Bioequivalence studies
• Bioanalytical services
• In-vitro permeation testing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Services: Phase I-IV clinical trial management services including clinical operations, site management, regulatory documentation, biostatistics, data management, medical writing, and pharmacovigilance for pharmaceutical and biotech sponsors
2. BA/BE Studies: Bioavailability and Bioequivalence studies for healthy subjects including PK/PD studies, clinical endpoint studies, and biosimilar studies with over 3000+ BE studies conducted
3. In-Vitro Studies: IVRT/IVPT studies, BCS biowaiver studies, in-vitro binding studies, drug characterisation for nasal spray and inhalation products, feeding tube studies
4. Special Studies: In-vivo tape stripping, dermal microdialysis, skin blanching studies, skin irritation testing, glucose clamp studies, veterinary BA/BE studies
5. Bioanalytical Services: Bioanalytical method development and validation services with anti-drug antibody (ADA) and neutralizing antibody (NAb) testing for biologics and biosimilars

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Raptim Research is a full-service Contract Research Organization (CRO) that provides end-to-end clinical research and bioanalytical services to pharmaceutical, biotechnology, medical device, and consumer healthcare sponsors. Its offerings span Phase I-IV clinical trials, bioequivalence/bioavailability (BA/BE) studies in healthy subjects, in-vitro release and permeation testing (IVRT/IVPT), and specialized dermatological and glucose clamp studies, supported by an in-house bioanalytical laboratory with over 600 validated methods.

Product overview

Raptim Research is a full-service Contract Research Organization (CRO) providing end-to-end clinical development services. The company operates four core service lines: Clinical Trials (Phase I-IV), BA/BE Studies (Bioavailability & Bioequivalence), In-Vitro Studies (IVRT/IVPT), and Special Studies. These services are supported by an integrated bioanalytical laboratory offering method development and validation with over 600 validated methods. The company has conducted 3,000+ BE studies and completed 150+ clinical trials across 18+ therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Phase I-IV clinical trial services including clinical operations, site management, regulatory documentation, biostatistics, data management, medical writing, medical monitoring, pharmacovigilance, and post-marketing surveillance across 18+ therapeutic areas, delivered for pharmaceutical, biotech, medical device, and consumer healthcare sponsors.
• BA/BE Studies (Bioavailability & Bioequivalence) Comprehensive bioequivalence and bioavailability study services for healthy subjects, including single/multi-dose studies, patient-based PK/PD, clinical endpoint studies, and biosimilar development. Raptim has conducted over 3,000 BE studies across its facilities.
• In-Vitro Studies In-Vitro Release Testing (IVRT) and In-Vitro Permeation Testing (IVPT) services for topical products, BCS Biowaiver studies, drug characterization for nasal and inhalation products, in-vitro binding studies, and feeding tube studies.
• Special Studies Specialized clinical studies including In-Vivo Tape Stripping, Glucose Clamp Studies, Dermal Microdialysis, Skin Blanching Studies, Skin Irritation and Sensitization Tests, and Veterinary BA/BE Studies.
• Bioanalytical Method Development and Validation Bioanalytical method development and validation services with a portfolio of over 600 validated methods covering APIs and complex matrices, including anti-drug antibody (ADA) and neutralizing antibody (NAb) testing for biologics and biosimilars, supporting pharmaceutical and biotech sponsors' bioanalytical and immunogenicity needs.

Quantifiable outcome

• Successfully cleared 32+ USFDA inspections
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cliantha Research: India-headquartered full-service CRO offering clinical trials, BA/BE, bioanalytical, and dermatology/cosmetics studies. Direct competitor to Raptim in healthy-volunteer BA/BE and complex generics across global regulatory submissions.
• Veeda Clinical Research: India-based CRO specializing in BA/BE, bioanalytical, and clinical research services for generic and biosimilar sponsors. Operates similar bed capacity and regulatory inspection footprint as Raptim, with overlapping sponsor lists.
• Lambda Therapeutic Research: India-headquartered CRO providing bioequivalence, clinical trial, bioanalytical, and Phase I-IV services. Closest head-to-head peer to Raptim given shared India base, healthy-volunteer BA/BE focus, and global regulatory inspection history.
• Accutest Research Laboratories: Indian CRO focused on bioanalytical method development, BA/BE, and clinical research for generic and NCE sponsors. Comparable to Raptim in bioanalytical depth and regulator-inspection track record.

Broad incumbents

• IQVIA: Largest global CRO offering end-to-end Phase I-IV, real-world evidence, and bioanalytical services. Represents the dominant incumbent that Raptim competes against for large multi-region pharma sponsors and broader clinical trial bundles.
• ICON plc: Top-tier global CRO acquired PRA Health Sciences, offering Phase I-IV, bioanalytical, and post-marketing services. Overlaps with Raptim on late-phase clinical operations and bioanalytical method validation work.
• Charles River Laboratories: Global CRO/CDMO with strong bioanalytical, safety assessment, and clinical trial services. Competitor to Raptim in bioanalytical method validation work for biologics/biosimilars and in clinical trial operations.
• Medpace: Mid-to-large global CRO specializing in Phase I-IV clinical trial management for pharma and biotech. Overlaps with Raptim on clinical operations particularly for biotech and specialty therapeutic area sponsors.

Regional players

• Syngene International: Indian listed CRO/CDMO offering discovery, development, and clinical research services. Competes with Raptim in India-based clinical and bioanalytical services, but operates at significantly larger scale and with public capital access.

Emerging players

• Piramal Pharma Solutions: India-headquartered CDMO/CRO with growing clinical and bioanalytical capabilities. Adjacent competitor to Raptim in pharma services outsourcing, although their primary focus is contract manufacturing rather than BA/BE studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInin.linkedin.com/company/raptim-research
• Xx.com/raptimresearch

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Raptim Research